| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 1195.34% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 08/18/2023 | 1195.34% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 08/18/2023 | 832.64% | HC Wainwright & Co. | $25 → $18 | Maintains | Buy |
| 08/18/2023 | 1143.52% | Needham | → $24 | Reiterates | Buy → Buy |
| 06/05/2023 | 1143.52% | Needham | → $24 | Reiterates | Buy → Buy |
| 04/19/2023 | 1143.52% | Needham | → $24 | Reiterates | → Buy |
| 04/03/2023 | 1143.52% | Needham | $33 → $24 | Maintains | Buy |
| 04/03/2023 | 1195.34% | Piper Sandler | $30 → $25 | Maintains | Overweight |
| 04/03/2023 | 1195.34% | HC Wainwright & Co. | $45 → $25 | Maintains | Buy |
| 08/31/2022 | 2231.61% | HC Wainwright & Co. | $70 → $45 | Maintains | Buy |
| 08/31/2022 | 1609.84% | Needham | $41 → $33 | Maintains | Buy |
| 08/30/2022 | 1454.4% | Piper Sandler | $35 → $30 | Maintains | Overweight |
| 08/17/2022 | 2024.35% | Needham | $72 → $41 | Maintains | Buy |
| 05/31/2022 | 3526.94% | HC Wainwright & Co. | $80 → $70 | Maintains | Buy |
| 05/31/2022 | 3630.57% | Needham | $85 → $72 | Maintains | Buy |
| 03/30/2022 | 4045.08% | HC Wainwright & Co. | $95 → $80 | Maintains | Buy |
| 11/01/2021 | 4304.15% | Needham | $83 → $85 | Maintains | Buy |
| 09/01/2021 | 4822.28% | HC Wainwright & Co. | $75 → $95 | Maintains | Buy |
| 06/10/2021 | 4563.21% | Cantor Fitzgerald | $76 → $90 | Maintains | Overweight |
| 06/02/2021 | — | Daiwa Capital | Initiates Coverage On | → Buy | |
| 03/15/2021 | 3786.01% | Needham | → $75 | Initiates Coverage On | → Buy |
| 03/03/2021 | 3786.01% | H.C. Wainwright | $55 → $75 | Maintains | Buy |
| 02/25/2021 | 3786.01% | Piper Sandler | → $75 | Initiates Coverage On | → Overweight |
| 12/07/2020 | 2749.74% | HC Wainwright & Co. | → $55 | Initiates Coverage On | → Buy |
| 08/26/2020 | 2039.9% | CMB International | → $41.3 | Initiates Coverage On | → Buy |
| 07/27/2020 | 2490.67% | Cantor Fitzgerald | → $50 | Initiates Coverage On | → Overweight |
| 02/14/2020 | 837.31% | CICC | → $18.09 | Initiates Coverage On | → Outperform |
| 02/12/2020 | 829.02% | China Renaissance | → $17.93 | Initiates Coverage On | → Buy |
| 02/11/2020 | 729.02% | Jefferies | → $16 | Initiates Coverage On | → Buy |
What is the target price for I-MAB (IMAB)?
The latest price target for I-MAB (NASDAQ: IMAB) was reported by Cantor Fitzgerald on September 5, 2023. The analyst firm set a price target for $25.00 expecting IMAB to rise to within 12 months (a possible 1195.34% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for I-MAB (IMAB)?
The latest analyst rating for I-MAB (NASDAQ: IMAB) was provided by Cantor Fitzgerald, and I-MAB reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for I-MAB (IMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of I-MAB, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for I-MAB was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
Is the Analyst Rating I-MAB (IMAB) correct?
While ratings are subjective and will change, the latest I-MAB (IMAB) rating was a reiterated with a price target of $0.00 to $25.00. The current price I-MAB (IMAB) is trading at is $1.93, which is within the analyst's predicted range.
